Neoviderm Skin Emulsion in the Prevention of Radiation Dermatitis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01701466 |
Recruitment Status :
Terminated
First Posted : October 5, 2012
Last Update Posted : May 25, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Head and Neck Cancer Breast Cancer | Other: Aveeno cream Other: Flamazine cream Other: NeoVIDERM cream | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 14 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | A Phase II Study Designed to Evaluate the Value of Neoviderm Skin Emulsion in the Prevention of Radiation Dermatitis for Patients Undergoing External Radiation Therapy |
Study Start Date : | December 2011 |
Actual Primary Completion Date : | May 2014 |

Arm | Intervention/treatment |
---|---|
Experimental: Arm B: standard of care plus NeoVIDERM cream
Patients will apply NeoVIDERM cream to the treatment area everyday one week before starting radiotherapy, throughout treatment and for two weeks post treatment. Patients will also perform standard of care skin treatment.
|
Other: Aveeno cream
Twice a day Other: Flamazine cream Twice a day, when there is dry desquamation Other: NeoVIDERM cream Three times a day |
Active Comparator: Arm A: standard skin care
Patients will be asked to apply Aveeno cream twice a day starting the day of their treatment until two weeks after the end of their treatments. If they develop dry desquamation, they will be asked to apply Flamazine twice a day until dermatitis resolves.
|
Other: Aveeno cream
Twice a day Other: Flamazine cream Twice a day, when there is dry desquamation |
- Maximum skin toxicity [ Time Frame: 7 weeks post beginning of radiation treatments ]The objective of this study is to determine the occurrence and degree of acute skin toxicity in patients receiving radical radiation therapy with preventive application of neoVIDERM compared to patients treated with institutional standard skin care.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion criteria: For patients receiving radiation to the breast
- Patients receiving a dose of at least 50 Gy in 25 fractions with concomitant chemotherapy or treated with the McGill technique.
- Patients able to understand and sign an informed consent form.
- Patients that do not have active connective tissue disorders.
- Patients 18 years or older.
- Patients that did not receive any previous radiation.
- Patients that do not have any known allergy to any ingredients of the NeoVIDERM cream
- Patients need to be able to apply the creams themselves or have help with applying the creams.
Inclusion criteria: For patients receiving radiation to the head and neck
- Patients receiving radiotherapy on fields that include both sides of the neck
- Patients able to understand and sign an informed consent form.
- Patients that do not have active connective tissue disorders.
- Patients 18 years or older.
- Patients that did not receive any previous radiation.
- Patients that do not have any known allergy to any ingredients of the NeoVIDERM cream
- Patients need to be able to apply the creams themselves or have help with applying the creams.
Exclusion criteria: For patients receiving radiation to the breast or the head and neck
-
Patients that have a type V or type VI skin type according to the Fitzpatrick scale (because these patients will likely have less radiodermatitis and if they do, it will be harder to evaluate it).
The Fitzpatrick Scale:
- Type I (scores 0-7) White; very fair; freckles. Always burns, never tans
- Type II (scores 8-16) White; fair. Usually burns, tans with difficulty
- Type III (scores 17-25) Beige; very common. Sometimes mild burn, gradually tans
- Type IV (scores 25-30) Beige with a brown tint; typical Mediterranean Caucasian skin.
Rarely burns, tans with ease
- Type V (scores over 30) Dark brown. Very rarely burns, tans very easily
- Type VI Black. Never burns, tans very easily
- Allergic to any ingredient in Neoviderm cream

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01701466
Canada, Quebec | |
Jewish General Hospital | |
Montreal, Quebec, Canada, H3T 1E2 |
Principal Investigator: | Te Vuong, MD | Jewish General Hospital |
Responsible Party: | Dr. Te Vuong, Director Radiation-oncology department, Sir Mortimer B. Davis - Jewish General Hospital |
ClinicalTrials.gov Identifier: | NCT01701466 |
Obsolete Identifiers: | NCT01470872 |
Other Study ID Numbers: |
11-053 |
First Posted: | October 5, 2012 Key Record Dates |
Last Update Posted: | May 25, 2015 |
Last Verified: | May 2015 |
Patients with |
Dermatitis Radiodermatitis Skin Diseases Radiation Injuries |
Wounds and Injuries Silver Sulfadiazine Anti-Infective Agents, Local Anti-Infective Agents |